文献速递心律失常

持续性房颤消融:Marshall静脉乙醇输注在个体化策略中的增益价值

Enhancing Persistent Atrial Fibrillation Ablation: The Added Value of Vein of Marshall Ethanol Infusion in a Tailored Strategy
RSS 订阅 · Journal of Cardiovascular Electrophysiology · 2026-10-06

该前瞻性单中心研究纳入118例持续性房颤患者,其中59例接受依据低电压区指导的个体化消融,并联合Marshall静脉乙醇输注,另59例为倾向评分匹配的单纯肺静脉隔离对照。结果显示个体化组术后1年房性心律失常复发率为13.5%,显著低于对照组的30.5%(p=0.02)。研究提示依据低电压区指导的个体化消融联合Marshall静脉乙醇输注可改善持续性房颤消融结局。

要点

  • 低电压区指导的个体化消融联合Marshall静脉乙醇输注可降低持续性房颤术后1年复发率。
  • 个体化组复发率为13.5%,显著低于单纯肺静脉隔离组的30.5%(p=0.02)。
  • 两组不良事件发生率无显著差异。

核心结论

  • 在持续性房颤患者中,依据低电压区指导的个体化消融联合Marshall静脉乙醇输注,与单纯肺静脉隔离相比,术后1年房性心律失常复发率显著更低。

研究设计与样本

  • 本研究为前瞻性单中心研究,纳入2022年8月至2024年8月期间接受持续性房颤导管消融的患者。
  • 共纳入118例患者,59例接受低电压区指导的个体化消融,59例为倾向评分匹配的单纯肺静脉隔离对照。
  • 个体化组中60%的患者接受了Marshall静脉乙醇输注,14%的患者因无低电压区而未在肺静脉外消融。

主要发现

  • 术后1年,个体化组房性心律失常复发率为13.5%,单纯肺静脉隔离组为30.5%,差异有统计学意义(p=0.02)。
  • 除2例患者外,所有消融线均实现双向阻滞。
  • 两组之间不良事件发生率无显著差异。

关键数值与推荐

  • 患者平均年龄为62±10岁,71%为男性。
  • 个体化组中60%的患者接受了Marshall静脉乙醇输注。
  • 14%的患者因无低电压区而未在肺静脉外进行消融。
  • 个体化组1年复发率为13.5%,对照组为30.5%(p=0.02)。

临床怎么用

  • 对于持续性房颤患者,可考虑依据低电压区存在与否制定个体化消融策略,而非一律仅行肺静脉隔离。
  • 在存在低电压区的患者中联合Marshall静脉乙醇输注,可能有助于降低术后1年房性心律失常复发。
  • 对于无低电压区的患者,仅行肺静脉隔离可能是合理的。

局限性

  • 该研究为单中心前瞻性研究,样本量相对有限。
  • 对照组采用倾向评分匹配而非随机分组,可能存在残余混杂。
  • 原文未报告长期随访超过1年的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Outcomes following catheter ablation for persistent atrial fibrillation (AF) remain suboptimal. Low-voltage areas (LVA), as a surrogate for atrial fibrosis, have been targeted due to their association with arrhythmia recurrence. Ethanol infusion in the vein of Marshall (VoM) has emerged as an adjunctive strategy that may enhance ablation efficacy. We evaluated the effectiveness of a tailored ablation strategy guided by the presence of LVA and incorporating VoM ethanol infusion in patients with persistent AF. Methods This prospective, single-center study included patients referred for catheter ablation for persistent AF ablation between August 2022 and August 2024. Patients underwent a tailored ablation strategy guided by the presence of LVA. Procedural endpoints and 1-year outcomes were assessed and compared with those of a propensity score-matched cohort undergoing pulmonary vein isolation (PVI) alone. Results A total of 118 patients (71% male, mean age of 62 ± 10years) were included in our study: 59 in the tailored approach group and 59 propensity score-matched controls. In the tailored group, VoM ethanol infusion was performed in 60% of patients, while ablation beyond pulmonary veins was not performed in 14% of patients due to LVA absence. Bidirectional block was achieved in all ablation lines except in two patients. At 1-year follow-up, 22% of patients had atrial arrhythmia recurrence. The risk of recurrence was significantly lower in the tailored approach group (13.5% vs. 30.5%, p = 0.02). A tailored approach was independently associated with freedom from atrial arrhythmia recurrence (HR 0.41 [0.17–0.94], p = 0.04). No significant differences in adverse events were observed between groups. Conclusions In patients with persistent AF, a tailored ablation guided by LVAs was associated with significantly lower arrhythmia recurrence at 1-year compared with PVI alone.

来源:Journal of Cardiovascular Electrophysiology,查看原文。版权归原作者所有。

引用

  1. Journal of Cardiovascular Electrophysiology:Enhancing Persistent Atrial Fibrillation Ablation: The Added Value of Vein of Marshall Ethanol Infusion in a Tailored Strategy

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。